US 12,031,008 B2
Dendritic macroporous hydrogels prepared by crystal templating
Scott Zawko, Austin, TX (US); and Christine Schmidt, Gainesville, FL (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Jul. 31, 2023, as Appl. No. 18/361,981.
Application 18/361,981 is a continuation of application No. 17/231,653, filed on Apr. 15, 2021, granted, now 11,760,858.
Application 17/231,653 is a continuation of application No. 16/597,106, filed on Oct. 9, 2019, granted, now 10,982,068, issued on Apr. 20, 2021.
Application 16/597,106 is a continuation of application No. 15/890,719, filed on Feb. 7, 2018, granted, now 10,442,911, issued on Oct. 15, 2019.
Application 15/890,719 is a continuation of application No. 15/135,978, filed on Apr. 22, 2016, granted, now 9,896,561, issued on Feb. 20, 2018.
Application 15/135,978 is a continuation of application No. 14/277,170, filed on May 14, 2014, granted, now 9,320,827, issued on Apr. 26, 2016.
Application 14/277,170 is a continuation of application No. 13/909,707, filed on Jun. 4, 2013, granted, now 8,728,499, issued on May 20, 2014.
Application 13/909,707 is a continuation of application No. 12/919,667, granted, now 8,668,863, issued on Mar. 11, 2014, previously published as PCT/US2009/035257, filed on Feb. 26, 2009.
Claims priority of provisional application 61/031,651, filed on Feb. 26, 2008.
Prior Publication US 2023/0383086 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C08J 9/26 (2006.01); A61L 26/00 (2006.01); A61L 27/52 (2006.01); B01J 13/00 (2006.01); C08B 37/00 (2006.01); C08B 37/08 (2006.01); C08B 37/16 (2006.01); C08H 1/06 (2006.01); C08J 3/075 (2006.01); C08J 3/24 (2006.01); C08J 3/28 (2006.01); C08J 5/10 (2006.01); C08J 5/18 (2006.01); C08K 5/00 (2006.01); C08K 5/21 (2006.01); C08L 5/00 (2006.01); C08L 5/04 (2006.01); C08L 5/10 (2006.01); C08L 5/16 (2006.01); C08L 89/06 (2006.01); C08J 3/26 (2006.01)
CPC C08J 9/26 (2013.01) [A61L 26/0023 (2013.01); A61L 26/0095 (2013.01); A61L 27/52 (2013.01); B01J 13/0065 (2013.01); C08B 37/0015 (2013.01); C08B 37/003 (2013.01); C08B 37/0045 (2013.01); C08B 37/0072 (2013.01); C08B 37/0075 (2013.01); C08B 37/0084 (2013.01); C08H 1/06 (2013.01); C08J 3/075 (2013.01); C08J 3/24 (2013.01); C08J 3/28 (2013.01); C08J 5/10 (2013.01); C08J 5/18 (2013.01); C08K 5/0025 (2013.01); C08K 5/0083 (2013.01); C08K 5/21 (2013.01); C08L 5/00 (2013.01); C08L 5/04 (2013.01); C08L 5/10 (2013.01); C08L 5/16 (2013.01); C08L 89/06 (2013.01); C08J 3/242 (2013.01); C08J 3/26 (2013.01); C08J 2201/0424 (2013.01); C08J 2205/022 (2013.01); C08J 2205/04 (2013.01); C08J 2207/10 (2013.01); C08J 2305/00 (2013.01); C08J 2305/04 (2013.01); C08J 2305/08 (2013.01)] 19 Claims
 
1. A system comprising:
a hydrogel composition; and
a protein coupled to the hydrogel composition;
wherein the hydrogel composition includes: (a) uncrosslinked hyaluronic acid; and (b) uncrosslinked alginate located around the uncrosslinked hyaluronic acid;
wherein the uncrosslinked alginate is configured to crosslink around the uncrosslinked hyaluronic acid with an ion when the uncrosslinked alginate is exposed to the ion;
wherein the uncrosslinked hyaluronic acid is not configured to crosslink with the ion when the uncrosslinked hyaluronic acid is exposed to the ion.